Addex, Michael J. Fox Foundation For Parkinson's Research deal

Addex received a $900,000 grant from the foundation to help fund a Phase II trial for ADX48621 to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID). Addex expects to start the trial next ...